{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:53:42Z","timestamp":1777917222023,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T00:00:00Z","timestamp":1228953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T00:00:00Z","timestamp":1228953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron"],"abstract":"<jats:p>Twelve patients with chronic renal failure (CRF) requiring dialysis, 7 of whom were hypercalcaemic, were treated with 24,25-dihydroxycholecalciferol [24,25(OH)&lt;sub&gt;2&lt;\/sub&gt;D&lt;sub&gt;3&lt;\/sub&gt;; 10 \u03bcg daily for 3 months] or placebo and the treatment then crossed over for a further 3 months. Treatment with 24,25(OH)&lt;sub&gt;2&lt;\/sub&gt;D&lt;sub&gt;3&lt;\/sub&gt; was associated with small but significant increments in the fractional rates of absorption of calcium (p &lt; 0.01) and phosphate (p &lt; 0.05) measured by a combined radioisotope test, but even during treatment, the absorption of both calcium and phosphate remained subnormal. A significant fall in immunoreactive parathyroid hormone (i-PTH) levels occurred during treatment (p &lt; 0.05) in the absence of significant changes in plasma ionised calcium and plasma phosphate levels. In 7 patients, treatment with 24,25(OH)&lt;sub&gt;2&lt;\/sub&gt;D&lt;sub&gt;3&lt;\/sub&gt; converted parathyroid glands which were non-suppressible by calcium infusion before treatment to suppressible ones ( &gt; 50% suppression of i-PTH levels) at similar levels of ionised calcium. 24,25(OH)&lt;sub&gt;2&lt;\/sub&gt;D&lt;sub&gt;3&lt;\/sub&gt; may have a role in the treatment of renal osteodystrophy, especially in patients with hypercalcaemic hyperparathyroidism.<\/jats:p>","DOI":"10.1159\/000186767","type":"journal-article","created":{"date-parts":[[2008,12,24]],"date-time":"2008-12-24T09:00:08Z","timestamp":1230109208000},"page":"286-291","source":"Crossref","is-referenced-by-count":9,"title":["Effect of 24,25- Dihydroxycholecalciferol on Intestinal Absorption of Calcium and Phosphate and on Parathyroid Hormone Secretion in Chronic Renal Failure"],"prefix":"10.1159","author":[{"given":"Z.","family":"Varghese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.F.","family":"Moorhead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Farrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2008,12,11]]},"container-title":["Nephron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/186767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000186767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:07:49Z","timestamp":1777658869000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000186767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000186767","archive":["Portico"],"relation":{},"ISSN":["1660-8151","2235-3186"],"issn-type":[{"value":"1660-8151","type":"print"},{"value":"2235-3186","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,11]]}}}